Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria

NCT02942420 is registered in ClinicalTrials.gov with Revive Therapeutics, Ltd. as lead sponsor.

NCT NCT02942420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02942420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria
Lead sponsor
Revive Therapeutics, Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2017
Completion date
March 31, 2018
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cystinuria